ReviewCancers2019
Predicting VTE in Cancer Patients: Candidate Biomarkers and Risk Assessment Models.
Review in Cancers, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05729464 (Risk Factors and Prediction Model of Cancer-associated Venous Thromboembolism), which is not on this map. Cited by 29 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Risk Factors and Prediction Model of Cancer-associated Venous Thromboembolism
Who cites it
29 citing papers in PubMed, 1 synthesis or guideline pooled it, 53 citations in OpenAlex.
- Pooled it
- Predictors of recurrent venous thromboembolism and major bleeding in patients with cancer: A secondary analysis of the CANVAS trial.Thrombosis research · 2024Trial
- Risk Assessment for Venous Thrombosis in Lymphoma and Emerging Biomarkers.International journal of molecular sciences · 2026Review
- Comparative analysis of risk prediction scores including all types of cancer-associated thrombosis.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026Observational
- Thrombopoiesis meets tumorigenesis: unlocking the diagnostic and prognostic potential of platelet indices in breast cancer- a narrative review.Annals of medicine and surgery (2012) · 2026Review
- Derivation of a novel risk assessment model of venous thromboembolism in hospitalized patients.PeerJ · 2026Article
- Development and validation of an explainable machine learning model for predicting postoperative venous thromboembolism in esophageal cancer.International journal of surgery (London, England) · 2026Article
- Development and validation of the CHI-CAT score: a novel tool for assessing cancer-associated venous thromboembolism risk in China.BMC cancer · 2025Article
- Association of coagulation-related indicators with postoperative venous thromboembolism occurrence in patients with pituitary tumors.Scientific reports · 2025Article
- Hypercoagulable state and effect of low-molecular-weight heparin prophylaxis on coagulation after lung cancer resection: results from thrombo-elastography.General thoracic and cardiovascular surgery · 2025Article
- The predictive value of risk assessment models for venous thromboembolism on gynaecological cancer patients.Journal of the colleges of medicine of South Africa · 2025Article
- Emerging Biomarkers for Assessing Thrombotic Risk in Patients Receiving Direct Oral Anticoagulants (DOACs).Cardiovascular & hematological agents in medicinal chemistry · 2025Review
- The Use of Artificial Intelligence in Predicting Chemotherapy-Induced Toxicities in Metastatic Colorectal Cancer: A Data-Driven Approach for Personalized Oncology.Diagnostics (Basel, Switzerland) · 2024Article
- Identifying novel biomarkers using proteomics to predict cancer-associated thrombosis.Bleeding, thrombosis and vascular biology · 2024Article
- Assessing the risk of venous thromboembolism in patients with haematological cancers using three prediction models.Journal of cancer research and clinical oncology · 2023Article
- Validation of venous thromboembolism predictive model in hematologic malignancies.Annals of hematology · 2023Article
- A nomogram for predicting the risk of venous thromboembolism in patients with solid cancers.Journal of thrombosis and thrombolysis · 2023Article
- Simple yet (more?) effective. Venous thromboembolism risk assessment model for germ cell tumour patients receiving first-line chemotherapy.Cancer medicine · 2023Article
- Thrombotic Pathogenesis and Laboratory Diagnosis in Cancer Patients, An Update.International journal of general medicine · 2023Review
- Cancer-Associated Thrombosis: A New Light on an Old Story.Diseases (Basel, Switzerland) · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 2 countries.
Funding
Abstract
Risk prediction of chemotherapy-associated venous thromboembolism (VTE) is a compelling challenge in contemporary oncology, as VTE may result in treatment delays, impaired quality of life, and increased mortality. Current guidelines do not recommend thromboprophylaxis for primary prevention, but assessment of the patient's individual risk of VTE prior to chemotherapy is generally advocated. In recent years, efforts have been devoted to building accurate predictive tools for VTE risk assessment in cancer patients. This review focuses on candidate biomarkers and prediction models currently under investigation, considering their advantages and disadvantages, and discussing their diagnostic performance and potential pitfalls.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.